Trial · NCT03336333
Outcomes22
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cohort 1: Progression-free Survival (PFS) as Determined by Independent Central Review (ICR) | Up to approximately 3 years and 7 months (as of cut-off date of 07MAY2021) | ITT analysis set included all enrolled participants who were assigned to a treatment group | Months | MEDIAN |
| SECONDARY | Cohort 1: Overall Response Rate (ORR) Between Treatment Groups as Determined by ICR | Up to 5 years | |||
| SECONDARY | Pooled Cohort 1/1a: Overall Response Rate (ORR) Between Treatment Groups | Up to 5 years | |||
| SECONDARY | Cohort 1: Overall Survival (OS) Between Treatment Groups as Determined by the ICR | Up to 5 years | |||
| SECONDARY | Cohort 1: Duration of Response (DOR) Between Treatment Groups as Determined by the ICR | Up to 5 years | |||
| SECONDARY | Pooled Cohort 1/1a: Duration of Response (DOR) Between Treatment Groups | Up to 5 years | |||
| SECONDARY | Cohort 1: Progression-free Survival (PFS) Between Treatment Groups Determined by Investigator Assessment (IA) | Up to 5 years | |||
| SECONDARY | Pooled Cohort 1/1a: Progression-free Survival (PFS) Between Treatment Groups Determined by Investigator Assessment (IA) | Up to 5 years | |||
| SECONDARY | Cohort 1: Patient-reported Outcomes as Assessed by the (European Quality Of Life 5D 5L) EQ-5D-5L Questionnaire | Up to 5 years | |||
| SECONDARY | Cohort 1: Patient-reported Outcomes as Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Questionnaire. | Up to 5 years | |||
| SECONDARY | Cohort 2: Overall Response Rate (ORR) | Up to 5 years | |||
| SECONDARY | Cohort 2: Progression-free Survival (PFS) | Up to 5 years | |||
| SECONDARY | Cohort 2: Duration of Response (DOR) | Up to 5 years | |||
| SECONDARY | Cohort 3: Overall Response Rate (ORR) | Up to 5 years | |||
| SECONDARY | Cohort 3: Progression-free Survival (PFS) | Up to 5 years | |||
| SECONDARY | Cohort 3: Duration of Response (DOR) | Up to 5 years | |||
| SECONDARY | Cohort 3: Rate of Undetectable Minimal Residual Disease (MRD4) | Up to 5 years | |||
| SECONDARY | Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Up to 5 years | |||
| SECONDARY | Apparent Rate of Clearance of Zanubrutinib From Plasma (CL/F)CL/F | Predose up to 12 hours postdose | |||
| SECONDARY | Cohort 1 Zanubrutinib Only Arms: Area-Under-Curve From Time 0 to 12 Hours Postdose (AUC0-12) | Predose up to 12 hours postdose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03336333/outcomes